Amadix — Series B · €3.2M

Amadix opened a €3.2M round in early November 2019: existing shareholders CRB Inverbío, Inveready, Alentia and Sodica put in about €2.2M, and the final tranche was raised on The Crowd Angel equity crowdfunding platform, which closed at €1.2M and was then extended by a further €400,000 to €1.37M from more than 250 individual investors. The funds were to cover regulatory approval of Colofast and make it available in hospitals from 2020.